NCT00792506 2022-02-02
Phase II Clinical Trial of ITF2357 In Patients With Relapsed/Refractory Multiple Myeloma
Italfarmaco
Phase 2 Terminated
Clinical Trials
6 trialsNCT01460940 2017-11-14
A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT00185302 2015-12-14
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma
Bayer
Phase 2 Completed
NCT01090973 2013-12-16
Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT00005624 2012-09-25
CI-994 in Treating Patients With Advanced Myeloma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT00866762 2011-12-12
A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia
Copenhagen University Hospital at Herlev
Phase 2 Unknown